Current management of pediatric dilated cardiomyopathy

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Purpose of Review: American and European guidelines for treatment of adult heart failure have been recently revised. This review will reconcile those guidelines to recent studies and experience in the treatment of pediatric dilated cardiomyopathy. Recent Findings: Therapy for pediatric dilated cardiomyopathy includes establishing a diagnosis for diagnostic-specific therapies as well as preventive strategies for anthracycline toxicity and muscular dystrophy. Pediatric studies demonstrate safety and efficacy for use of angiotensin-converting enzyme inhibition and beta-blockers in dilated cardiomyopathy. Cardiac resynchronization and mitral annuloplasty represent potential nonpharmacologic therapies. Implantable defibrillator therapy may be of less import in children as compared with adults. Ventricular assist devices (VADs) are now available for all ages, which can improve survival and potentially can lead to recovery. Summary: The robust development of new therapies for adult heart failure has been successfully applied to children with dilated cardiomyopathy. Therapies for severe, intractable heart failure have been more widely utilized than therapies for mild-to-moderate heart failure.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalCurrent Opinion in Cardiology
Issue number2
StatePublished - Mar 2010


  • Dilated cardiomyopathy
  • Pediatrics
  • Treatment


Dive into the research topics of 'Current management of pediatric dilated cardiomyopathy'. Together they form a unique fingerprint.

Cite this